Archive | Biopharmaceuticals

Biopharma Market Re-Ignited by News and NASDAQ Strength

follow The IBB hit another new high today at $118.85 as the biotech bull market rolls on. Our index of biopharmaceutical stocks were up 4% at one time propelled by Medivation (MDVN $67.67) up 22% on favorable clinical news on its prostate cancer drug. A WSJ story helped move the stock. Medivation has no revenue and […]

Continue Reading 0

Rayno Biopharmaceuticals Portfolio 2/09/09-1/27/12

neurontinnorx Rayno Life Science Biopharmaceutical Picks Beat All Sector Averages Life Science Market  Hits 10 Year High Tracked by IBB ($115.51), and Up 46% Over 5 years Highlights of Rayno Biopharma Portfolio Biggest winners over 3 years were Alexion, Biogen, Micromet, Regeneron, Targacept and Viropharma. Targacept was at one time was a 20X return but is […]

Continue Reading 0

Rayno Life Science Portfolio: Another Buyout- MITI Goes for $1.16B

see url M&A Trend Picks Up Steam The beat goes on as Amgen agrees to buy Micromet (MITI $10.95) for $1.16B.Micromet is focused on treatment  of hematologic malignancies with its BiTE monoclonal antibody platform and has four clinical stage  product candidates. The stock was $5 on November 25 ,2011. Micromet was added to the Rayno Life Science […]

Continue Reading 0

“January Effect” Traders: Take Some Profits

If you followed our trades from November /December you made at least 20% so why push it? The Rayno Life Science Portfolio is down 0.75% today in a choppy  market. Our mid-cap biopharmaceutical index is down 0.87% but diagnostics and tools are  down only 0.3% as they were hit hard over the past 3 months. […]

Continue Reading 0

“January Effect” Rolls On with Biotech Stocks Up Over 1%, 9.3% MTD

Seems a Bit Frothy Large and mid-cap biopharmaceutical stocks continued to surge today with the bellwether ETF IBB ($114) hitting one year highs of $114.15 today. Many of our recent focus picks also continue to roll ahead: Astex (ASTX $2.18) up 4.8%, Gilead (GILD $47.40) up 2.4%,ImmunoGen (IMGN $12.75) up 3.3%, Seattle Genetics (SGEN $18) up […]

Continue Reading 0

Biotechnology Stock Review 2011:Update 1/2/12

Here are some key points from our 2011 Biotech Stock Review posted in Investor Uprising: Winners from the 2011 Rayno Life Science Portfolio: Abaxis (ABAX), Alexion(ALXN), Amgen (AMGN), Biogen(BIIB), Bristol-Myers (BMY),Celera(acquired),Cephalon (acquired) Cubist (CBST), Exact Scientific (EXAS),Gilead (GILD), BioETF (IBB), Immucor (acquired), Neogen (NEOG), Regeneron (REGN),Quidel (QDEL), Seattle Genetics (SGEN), United Therapeutics(UTHR) and Viropharma (VPHM) Losers: Alere […]

Continue Reading 0

Three Small Cap Stocks for a Rebound in January: AMRI,ASTX,SRLS-UPDATE 1/5/12

January Rally on Schedule for Small Cap Biotech Stocks Three Picks we made on December 14: Albany Molecular (AMRI $2.89) Up 16% Astex Pharmaceuticals (ASTX $1.94) Up 19% SeraCare (SRLS $3.00) Up 1.7% Three healthcare conferences in San Francisco next week Jan. 9-13 should provide news and perhaps another boost for biotech stocks: J.P.Morgan Healthcare […]

Continue Reading 0

Rayno Life Science Portfolios Run With NASDAQ Up 3.79%

Life Science Stocks Have a Big Day  The Rayno Biopharmaceutical Portfolio was up over 3.7% today as all biotechnology stocks pretty much tracked NASDAQ which was up 3.5%. Although we remain cautious with no new buys we have  a good chance for a Q4 rally as the sector is outperforming NASDAQ quarter to date. Within […]

Continue Reading 0

Gilead (GILD) $11B Deal for Pharmasset (VRUS) Sparks Biotech Stocks

Pharmasset Buyout Brings To Mind M&A Upside for Biotech Stocks: ETF’s and Funds Lead the Way Gilead (GILD $35) stepped up with a huge buyout of Pharmasset (VRUS $134.21) driving the stock up 89% over Fridays’ close and 519% YTD! Pharmasset has no revenues but has a three potential hepatitis-C treatments in clinical trials that […]

Continue Reading 0

Caution on Biotechs With Risk Off Situation-UPDATE 1/5/12 Dendreon Soars

Dendreon (DNDN $10.94) soared 44% today on a business update saying Provenge sales for its prostate cancer treatment were better than expected. Fourth quarter gross revenues were $82M with full year revenues at  $228M .Also the Center for Medicare and Medicaid Services updated their reimbursement landscape.   Time to Look at Dendreon (DNDN) We have been […]

Continue Reading 0